Multidisciplinary Care and Supplemental Therapy in Clear-Cell RCC

News
Video

Insight into the importance of patient-centered care, highlighting the role of a multidisciplinary team in managing advanced renal cell carcinoma and addressing questions regarding alternative medications.

Summary:

In the context of advanced renal cell carcinoma (RCC) treatment, a patient-centered approach is crucial, considering the overwhelming nature of a cancer diagnosis. The initial clinic visits are focused on understanding the patient’s emotional state, coping mechanisms, and comprehension of their diagnosis. Building a shared understanding between the healthcare team and the patient forms the foundation for informed decision-making.

The multidisciplinary team, comprising oncology nurse navigators, social workers, and pharmacists, plays a pivotal role in managing patients starting systemic therapy for kidney cancer. Emphasis is placed on the collaboration with pharmacists to navigate the complexities of adverse effects, especially when managing overlapping symptoms caused by tyrosine kinase inhibitors (TKIs) and immunotherapies. Addressing issues such as diarrhea, a common adverse effect, involves the expertise of the pharmacy team to differentiate contributing factors and tailor interventions. Supplement use, including herbal and alternative medications, is a common concern for patients seeking relief from cancer-related symptoms or adverse effects. The multidisciplinary approach allows for multiple clinicians to inquire about patient medications, ensuring a comprehensive understanding. Pharmacists engage in separate conversations, providing a dedicated space for patients to discuss alternative treatments. The team considers available data on drug interactions, toxicities, and expected adverse effects of herbal supplements. The cautious approach prioritizes patient safety, presenting data when available and allowing patients to continue certain supplements if deemed safe.

The multidisciplinary team’s collaboration extends to addressing questions about using supplements, recognizing potential drug interactions and liver metabolism issues. In-depth discussions help patients comprehend the totality of their care, fostering a collaborative decision-making process. Beyond medical interventions, the team considers quality of life, highlighting the importance of improving patient outcomes beyond survival metrics. The patient-centered, multidisciplinary approach not only addresses the complexities of advanced RCC treatment but also emphasizes the importance of considering the patient’s values and goals in shaping their care journey.

Summary is AI-generated and reviewed by Cancer Network editorial staff.

Recent Videos
A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Rohit Gosain, MD; Sumanta Kumar Pal, MD, FASCO; and Rahul Gosain, MD, presenting slides
Related Content